U.S. Compounding Pharmacies Market Size By Pharmacy Type (503A, 503B), By Sterility (Sterile, Non-sterile), By Product (Oral, Topical, Rectal, Parenteral, Nasal, Ophthalmic, Otic), By Application (Paediatric, Adult, Geriatric, Veterinary), By Compounding Type (Pharmaceutical Ingredient Alteration [PIA], Currently Unavailable Pharmaceutical Manufacturing [CUPM], Pharmaceutical Dosage Alteration [PDA]), By Therapeutic Area (Hormone Replacement, Pain Management, Dermatology, Specialty Drugs, Nutritional Supplements) Industry Analysis Report, Application Potential, Price Trends, Competitive Market Share & Forecast, 2018 – 2025

Published Date: Oct 2018  |  Report ID: GMI2961  |  Authors: Sumant Ugalmugale

Report Format: PDF   |   Pages: 110   |   Base Year: 2017




Summary Table of Contents Industry Coverage Methodology

Report Content

Chapter 1.  Methodology

1.1. Methodology

1.2. Market definitions

1.3. Forecast parameters          

1.4. Data sources

1.4.1.  Secondary

1.4.1.1.  Paid sources

1.4.1.2.  Unpaid sources

1.4.2.  Primary

Chapter 2.  Executive Summary

2.1. U.S. compounding pharmacies industry 3600 synopsis, 2014 - 2025

Chapter 3.  U.S. Compounding Pharmacies Industry Insights

3.1. Industry segmentation

3.2. Industry size and forecast, 2014 – 2025

3.3. Industry impact forces

3.3.1.  Growth drivers

3.3.1.1. Increasing geriatric population and improved longevity

3.3.1.2. Growing acceptance of personalized medicines

3.3.1.3. Increasing drug shortage in the country

3.3.1.4.    Convenience of using compounded drugs

3.3.1.5. Growing demand for compounded bioidentical menopausal hormone therapy (BMHT) among women

3.3.2.  Industry pitfalls & challenges

3.3.2.1. Changing regulatory specifications

3.3.2.2.    Issues related to safety standards of compounded drugs

3.4. Growth potential analysis

3.4.1.  By pharmacy type

3.4.2.  By sterility

3.4.3.  By product

3.4.4.  By application

3.4.5.  By compounding type

3.4.6.  By therapeutic area

3.5. Regulatory landscape

3.6. Reimbursement landscape

3.7. Innovative compounding technologies

3.7.1.  Web-based quality management system

3.7.2.  Digital tools

3.8. Porter’s analysis

3.9. Competitive landscape, 2017

3.9.1.   Strategy dashboard

3.10.  PESTEL analysis

Chapter 4.  U.S. Compounding Pharmacies Market, By Pharmacy Type

4.1. U.S. compounding pharmacies market share, by pharmacy type, 2017 & 2025

4.2. 503A compounding pharmacy

4.2.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

4.3. 503B compounding pharmacy

4.3.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

Chapter 5.  U.S. Compounding Pharmacies Market, By Sterility

5.1. U.S. compounding pharmacies market share, by sterility, 2017 & 2025

5.2. Sterile

5.2.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

5.3. Non-sterile

5.3.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

Chapter 6.  U.S. Compounding Pharmacies Market, By Product

6.1. U.S. compounding pharmacies market share, by product, 2017 & 2025

6.2. Oral

6.2.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.2.  Solid preparations

6.2.2.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.2.2.  Tablets

6.2.2.2.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.2.3.  Capsules

6.2.2.3.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.2.4.  Granules

6.2.2.4.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.2.5.  Powder

6.2.2.5.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.2.6.  Others

6.2.2.6.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.3.  Liquid preparations

6.2.3.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.3.2.  Solutions

6.2.3.2.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.3.3.  Suspension

6.2.3.3.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.3.4.  Emulsion

6.2.3.4.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.3.5.  Syrup

6.2.3.5.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.2.3.6.  Others

6.2.3.6.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.3. Topical

6.3.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.3.2.  Ointments

6.3.2.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.3.3.  Creams

6.3.3.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.3.4.  Gels

6.3.4.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.3.5.  Pastes

6.3.5.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.3.6.  Others

6.3.6.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.4. Rectal

6.4.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.4.2.  Suppositories

6.4.2.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.4.3.  Enema

6.4.3.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.4.4.  Others

6.4.4.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.5. Parenteral

6.5.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.5.2.  Large Volume Parenteral (LVP)

6.5.2.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.5.3.  Small Volume Parenteral (SVP)

6.5.3.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.6. Nasal

6.6.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.7. Ophthalmic

6.7.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

6.8. Otic

6.8.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

Chapter 7.  U.S. Compounding Pharmacies Market, By Application

7.1. U.S. compounding pharmacies market share, by application, 2017 & 2025

7.2. Pediatric

7.2.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

7.3. Adult

7.3.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

7.4. Geriatric

7.4.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

7.5. Veterinary

7.5.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

Chapter 8.   U.S. Compounding Pharmacies Market, By Compounding Type

8.1. U.S. compounding pharmacies market share, by compounding type, 2017 & 2025

8.2. Pharmaceutical Ingredient Alteration (PIA)

8.2.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

8.3. Currently Unavailable Pharmaceutical Manufacturing (CUPM)

8.3.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

8.4. Pharmaceutical Dosage Alteration (PDA)

8.4.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

8.5. Others

8.5.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

Chapter 9.  U.S. Compounding Pharmacies Market, By Therapeutic Area

9.1. U.S. compounding pharmacies market share, by therapeutic area, 2017 & 2025

9.2. Hormone Replacement

9.2.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

9.3. Pain Management

9.3.1.  U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

9.4. Dermatology

9.4.1. U.S. compounding pharmacies market size, 2014 - 2025 (USD Mn)

9.5. Specialty Drugs

9.5.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

9.6. Nutritional Supplements

9.6.1. U.S. compounding pharmacies market size, 2014 – 2025 (USD Mn)

9.7. Others

9.7.1. U.S. compounding pharmacies market size, 2014 - 2025 (USD Mn)

Chapter 10.  Company Profiles

10.1.  Absolute Pharmacy

10.1.1.   Business overview

10.1.2.   Financial data

10.1.3.   Product landscape

10.1.4.   Strategic outlook

10.1.5.   SWOT analysis

10.2.  B. Braun Medical

10.2.1.   Business overview

10.2.2.   Financial data

10.2.3.   Product landscape

10.2.4.   Strategic outlook

10.2.5.   SWOT analysis

10.3.  Cantrell Drug Company

10.3.1.   Business overview

10.3.2.   Financial data

10.3.3.   Product landscape

10.3.4.   Strategic outlook

10.3.5.   SWOT analysis

10.4.  Clinigen Group

10.4.1.   Business overview

10.4.2.   Financial data

10.4.3.   Product landscape

10.4.4.   Strategic outlook

10.4.5.   SWOT analysis

10.5.  Dougherty’s Pharmacy

10.5.1.   Business overview

10.5.2.   Financial data

10.5.3.   Product landscape

10.5.4.   Strategic outlook

10.5.5.   SWOT analysis

10.6.  Fagron

10.6.1.   Business overview

10.6.2.   Financial data

10.6.3.   Product landscape

10.6.4.   Strategic outlook

10.6.5.   SWOT analysis

10.7.  Fresenius Kabi

10.7.1. Business overview

10.7.2.  Financial data

10.7.3.  Product landscape

10.7.4.  Strategic outlook

10.7.5.  SWOT analysis

10.8.   Institutional Pharmacy Solutions

10.8.1.   Business overview

10.8.2.   Financial data

10.8.3.   Product landscape

10.8.4.   Strategic outlook

10.8.5.   SWOT analysis

10.9.   Lorraine’s Pharmacy

10.9.1.   Business overview

10.9.2.   Financial data

10.9.3.   Product landscape

10.9.4.   Strategic outlook

10.9.5.   SWOT analysis

10.10. McGuff Compounding Pharmacy Services

10.10.1. Business overview

10.10.2. Financial data

10.10.3. Product landscape

10.10.4. Strategic outlook

10.10.5. SWOT analysis

10.11. McKesson Corporation

10.11.1. Business overview

10.11.2. Financial data

10.11.3. Product landscape

10.11.4. Strategic outlook

10.11.5. SWOT analysis

10.12. Nephron Pharmaceuticals

10.12.1. Business overview

10.12.2. Financial data

10.12.3. Product landscape

10.12.4. Strategic outlook

10.12.5. SWOT analysis

10.13. Pencol Compounding Pharmacy

10.13.1. Business overview

10.13.2. Financial data

10.13.3. Product landscape

10.13.4. Strategic outlook

10.13.5. SWOT analysis

10.14. Pentec Health

10.14.1. Business overview

10.14.2. Financial data

10.14.3. Product landscape

10.14.4. Strategic outlook

10.14.5. SWOT analysis

10.15. PharMEDium

10.15.1. Business overview

10.15.2. Financial data

10.15.3. Product landscape

10.15.4. Strategic outlook

10.15.5. SWOT analysis

10.16. Premier Pharmacy Labs

10.16.1. Business overview

10.16.2. Financial data

10.16.3. Product landscape

10.16.4. Strategic outlook

10.16.5. SWOT analysis

10.17. Rx3 Compounding Pharmacy

10.17.1. Business overview

10.17.2. Financial data

10.17.3. Product landscape

10.17.4. Strategic outlook

10.17.5. SWOT analysis

10.18. RXQ Compounding Pharmacy

10.18.1. Business overview

10.18.2. Financial data

10.18.3. Product landscape

10.18.4. Strategic outlook

10.18.5. SWOT analysis

10.19. Triangle Compounding Pharmacies

10.19.1. Business overview

10.19.2. Financial data

10.19.3. Product landscape

10.19.4. Strategic outlook

10.19.5. SWOT analysis

10.20. Wedgewood Village Pharmacy

10.20.1. Business overview

10.20.2. Financial data

10.20.3. Product landscape

10.20.4. Strategic outlook

10.20.5. SWOT analysis

10.21. Wells Pharmacy Network

10.21.1. Business overview

10.21.2. Financial data

10.21.3. Product landscape

10.21.4. Strategic outlook

10.21.5. SWOT analysis

 

Data Tables

TABAL 1.    U.S. compounding pharmacies industry 360° synopsis, 2014 – 2025

TABAL 2.    U.S. compounding pharmacies market, 2014 – 2025 (USD Million)

TABAL 3.    Industry impact forces

TABAL 4.    U.S. compounding pharmacies market, by pharmacy type, 2014 – 2025 (USD Million)

TABAL 5.    U.S. compounding pharmacies market, by sterility, 2014 – 2025 (USD Million)

TABAL 6.    U.S. compounding pharmacies market, by product, 2014 – 2025 (USD Million)

TABAL 7.    U.S. compounding pharmacies oral market, 2014 – 2025 (USD Million)

TABAL 8.    U.S. compounding pharmacies solid preparations market, 2014- 2025, (USD Mn)

TABAL 9.    U.S. compounding pharmacies liquid preparations market, 2014 - 2025, (USD Million)

TABAL 10.    U.S. compounding pharmacies topical market, 2014 - 2025, (USD Million)

TABAL 11.    U.S. compounding pharmacies rectal market, 2014 – 2025 (USD Million)

TABAL 12.    U.S. compounding pharmacies market, by application, 2014 – 2025 (USD Million)

TABAL 13.    U.S. compounding pharmacies market, by compounding type, 2014 – 2025 (USD Million)

TABAL 14.    U.S. compounding pharmacies market, by therapeutic area, 2014 – 2025 (USD Million)
 

Charts & Figures

FIG. 1    Industry segmentation

FIG. 2    U.S. compounding pharmacies market, 2014 – 2025 (USD Million)

FIG. 3    Growth potential analysis, by pharmacy type

FIG. 4    Growth potential analysis, by sterility

FIG. 5    Growth potential analysis, by product

FIG. 6    Growth potential analysis, by application

FIG. 7    Growth potential analysis, by compounding type

FIG. 8    Growth potential analysis, by therapeutic area

FIG. 9    Porter’s Analysis

FIG. 10    Strategic Dashboard

FIG. 11    PESTEL Analysis

 

Buy Now

Single User: $2,850 Access to only 1 person; cannot be shared; cannot be printed
Multi User: $4,850 Access for 2 to 5 users only within same department of one company
Enterprise User: $6,850 Access to a company wide audience; includes subsidiary companies or other companies within a group of companies

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

Why Global Market Insights, Inc.?

Reliability & accuracy

  • GMI is unparalleled when to comes to the quality of research and information provided to clients. Our unique methodology is designed to ensure a minimum of 90% accuracy to give our clients excellent value on their investment.

Quality & trust


  • BBB Rating - Click to Verify

Customer service

  • Over 200 experts are available across various time-zones, ready to serve clients for their research needs. Our industry experts help clients to design reports customized to their needs.

Security & compliance

We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X